Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: It remains unknown whether complete revascularisation is optimally performed in patients with ST segment elevation myocardial infarction (STEMI) during the index or at staged procedures. The aims of this study were to quantify the number of primary percutaneous coronary intervention (PCI) procedures in which non-culprit lesions needed further evaluation, to determine the consequence of the re-evaluation and to quantify adverse cardiac events during the waiting time for re-evaluation and intervention.
Methods: The study was observational and retrospective and included all patients with STEMI treated with primary PCI during 1 year at our centre.
Results: Among the 507 patients with STEMI, 374 were considered sufficiently treated with culprit lesion PCI only. Complete primary multivessel revascularisation was performed in 11 patients. Non-culprit lesion re-evaluation was planned for 122 patients (24%). Of these 122 patients, 3 patients died during their index admission. Follow-up data were not available for 3 patients. Among the 116 patients, 187 non-culprit lesions were re-evaluated and 77 patients (66.4%) underwent revascularisation with treatment of 119 lesions (63.3%). Re-evaluation was performed after a median of 30 days (25th centile: 9 days, 75th centile: 35 days). During the waiting time for re-evaluation, two patients underwent a new primary PCI due to stent thrombosis of the index culprit lesion.
Conclusions: Staged re-evaluation of non-culprit lesions observed in patients with STEMI was required in 24% of a primary PCI cohort. Intervention was performed in 66.4% of patients scheduled for re-evaluation. We observed no adverse events related to the non-culprit lesions during the waiting time for a staged re-evaluation or intervention.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932309 | PMC |
| http://dx.doi.org/10.1136/openhrt-2016-000427 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validation of angiography-based FFR in non-culprit vessels of patients presenting with STEMI.
Clin Res Cardiol
September 2025
Department of (Interventional) Cardiology, Thoraxcenter, Erasmus University Medical Center, Room Rg-628, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.
Background: Fractional flow reserve (FFR) for non-culprit lesions (NCLs) in patients with ST-elevation myocardial infarction (STEMI) can be influenced by temporary changes in microvascular resistance. Angiography-derived vessel fractional flow reserve (vFFR) has been tested as a less-invasive alternative.
Aims: The FAST STEMI II study aimed to assess the diagnostic performance of acute-setting vFFR vs.
Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial.
Lancet
September 2025
Division of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Chonnam National University, Gwangju, South Korea. Electronic address:
Background: The optimal timing of complete revascularisation for patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease remains unclear. We aimed to assess whether immediate complete revascularisation was non-inferior to staged complete revascularisation during the index admission.
Methods: We conducted an open-label, randomised, non-inferiority trial at 14 hospitals in South Korea.
The impact of virtual fractional flow reserve on revascularization strategy in ST-elevation myocardial infarction with multivessel disease.
Eur Heart J Open
July 2025
Institut Cardiovasculaire Paris-Sud, Hôpital Jacques Cartier, Ramsay-Santé, 6 Avenue du Noyer Lambert, Massy 91300, France.
Association between residual cholesterol and vulnerable non-culprit lesions progressing to major adverse cardiovascular events.
Front Endocrinol (Lausanne)
September 2025
Department of Children's Heart Center, Fuwai Central China Cardiovascular Hospital, Zhengzhou University Central China Fuwai Hospital, Zhengzhou, China.
Background: Residual cholesterol (RC), a key indicator of lipid metabolism disorders, has been increasingly implicated in atherosclerotic progression. However, its association with vulnerable thin-cap fibroatheromas (TCFA) in non-culprit coronary lesions (NCCLs) and the subsequent risk of major adverse cardiovascular events (MACE) remains insufficiently explored.
Methods: In this prospective observational study conducted between June 2022 and September 2023, patients diagnosed with TCFA within NCCLs were followed for at least 12 months.
Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study.
Eur Heart J
September 2025
Department of Cardiology, Radboud University Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands.
Background And Aims: Coronary thin-cap fibroatheromas (TCFA) are associated with adverse outcome, but identification of TCFA requires expertise and is highly time-demanding. This study evaluated the utility of artificial intelligence (AI) for TCFA identification in relation to clinical outcome.
Methods: The PECTUS-AI study is a secondary analysis from the prospective observational PECTUS-obs study, in which 438 patients with myocardial infarction underwent optical coherence tomography (OCT) of all fractional flow reserve-negative non-culprit lesions (i.